National Planning Corp cut its position in Sanofi (NYSE:SNY) by 1.0% during the second quarter, Holdings Channel reports. The institutional investor owned 10,142 shares of the company’s stock after selling 98 shares during the period. National Planning Corp’s holdings in Sanofi were worth $485,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Pennsylvania Trust Co increased its stake in Sanofi by 0.4% in the second quarter. Pennsylvania Trust Co now owns 8,314 shares of the company’s stock worth $402,000 after buying an additional 37 shares in the last quarter. Rehmann Capital Advisory Group increased its stake in Sanofi by 0.7% in the second quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock worth $347,000 after buying an additional 47 shares in the last quarter. Weik Investment Services Inc. increased its stake in Sanofi by 0.9% in the first quarter. Weik Investment Services Inc. now owns 5,895 shares of the company’s stock worth $267,000 after buying an additional 50 shares in the last quarter. Financial Advisors Network Inc. increased its stake in Sanofi by 1.0% in the first quarter. Financial Advisors Network Inc. now owns 8,282 shares of the company’s stock worth $409,000 after buying an additional 84 shares in the last quarter. Finally, First City Capital Management Inc. increased its stake in Sanofi by 0.3% in the first quarter. First City Capital Management Inc. now owns 38,289 shares of the company’s stock worth $1,733,000 after buying an additional 100 shares in the last quarter. 9.96% of the stock is currently owned by institutional investors.

Sanofi (NYSE:SNY) opened at 47.55 on Friday. The company has a 50 day moving average price of $47.99 and a 200-day moving average price of $46.11. Sanofi has a one year low of $36.81 and a one year high of $50.24. The firm has a market capitalization of $119.42 billion, a PE ratio of 11.23 and a beta of 0.88.

Sanofi (NYSE:SNY) last posted its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.74. The company had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business’s revenue for the quarter was down 2.3% on a year-over-year basis. On average, equities analysts predict that Sanofi will post $3.26 EPS for the current year.

TRADEMARK VIOLATION WARNING: “National Planning Corp Cuts Stake in Sanofi (SNY)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/national-planning-corp-cuts-stake-in-sanofi-sny/1481311.html.

SNY has been the topic of a number of recent research reports. BidaskClub cut Sanofi from a “buy” rating to a “hold” rating in a report on Friday, June 9th. Argus lifted their target price on Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, June 9th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Friday, June 2nd. Berenberg Bank cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Finally, TheStreet upgraded Sanofi from a “c+” rating to a “b-” rating in a report on Monday, April 24th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $63.75.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.